Get started
Author

Mihály Makara

Observed names: M Makara, M. Makara, Makara Mihály, Makara, Mihály, Mihaly Makara
ORCID: 0000-0001-5456-8409
Observed ORCID: 0000-0001-5456-8409
OpenAlex ID: A5028989048
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
2016 · Sarah Blach, Stefan Zeuzem, et al. · The Lancet. Gastroenterology & hepatology · 2,099
PDF
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
2019 · Zobair M Younossi, Vlad Ratziu, et al. · The Lancet · 1,328
PDF
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
2017 · Alison D Marshall, Evan B Cunningham, et al. · The Lancet. Gastroenterology & hepatology · 161
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)
2019 · Markus Peck‐Radosavljevic, Krzysztof Simon, et al. · Hepatology · 152
PDF
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
2015 · Eric Lawitz, Mihály Makara, et al. · Gastroenterology · 88
PDF
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3
2015 · A. Sibley, K. H. Han, et al. · Journal of Viral Hepatitis · 80
PDF
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
2024 · Alison D Marshall, Alex R Willing, et al. · The Lancet. Gastroenterology & hepatology · 79
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection ( ESSENTIAL II )
2015 · S. Zeuzem, R. Flisiak, et al. · Alimentary Pharmacology & Therapeutics · 50
PDF
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
2015 · Stefan Zeuzem, Christophe Hézode, et al. · Journal of Hepatology · 43
PDF
Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report
2015 · Mihály Makara, Mihály Sulyok, et al. · Journal of Clinical Virology · 32
Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study
2015 · Mihály Sulyok, Mihály Makara, et al. · European Journal of Gastroenterology & Hepatology · 28
Predictive value of psychosocial assessment for the mortality of patients waiting for liver transplantation
2015 · Gábor Gazdag, G Gergely Horváth, et al. · Psychology Health & Medicine · 23
Non-Hodgkin Lymphoma and Hepatitis C: Where We are and What Next?
2014 · Mihály Sulyok, Mihály Makara, et al. · Pathology & Oncology Research · 16
Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe
2017 · A.D. Marshall, S. Nielsen, et al. · Journal of Hepatology · 15
Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis
2014 · Benjamin Maasoumy, Bela Hunyady, et al. · PLoS ONE · 15
PDF
Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents
2022 · Klára Werling, Béla Hunyady, et al. · Viruses · 14
PDF
Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures
2021 · Robert Flisiak, Krasimir Antonov, et al. · Journal of Clinical Medicine · 12
PDF
Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline
2014 · Béla Hunyady, Judit Gervain, et al. · Orvosi Hetilap · 9
PDF
Effect of hepatitis C infection on the quality of life
2018 · Gergely Horváth, Teodóra Keleti, et al. · Perspectives In Psychiatric Care · 8
PDF
Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy
2018 · Béla Hunyady, Margit Abonyi, et al. · Clinical and Experimental Hepatology · 7
PDF
New therapeutic options for HCV in Central Europe
2016 · Robert Flisiak, Petr Urbánek, et al. · Clinical and Experimental Hepatology · 7
PDF
Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis
2012 · Mihály Makara, Gábor Horváth, et al. · Orvosi Hetilap · 7
PDF
A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2017. szeptember 22-től
2018 · Gábor Horváth, Zsuzsanna Gerlei, et al. · Orvosi Hetilap · 6
A hepatitis C-vírus-fertőzés szűrése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. Magyar konszenzusajánlás. Érvényes: 2017. = Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 22 September 2017 szeptember 22-től
2017 · Béla Hunyady, Zsuzsanna Gerlei, et al. · 6
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin (3D + RBV) Treatment of Hepatitis C (HCV) Genotype 1 (GT1) Infected Patients (pts) after Failure to Previous First Generation Protease-Inhibitor (PI) Therapy Interim Analysis
2016 · B. Hunyady, M. Abonyi, et al. · Journal of Hepatology · 6
Works count: 65
Citation count: 4,347
H-index: 15
I10-index: 17
Year
Topic
Type